• 作者：José ; Ignacio Minguela<sup> ; sup><sup>joseignacio.minguelapesquera@osakidetza.netsup> ; Marí ; a Á ; ngeles Moraza ; Alejandro Chena ; Isabel Jimeno ; Julen Ocharan-Corcuera ; Ramó ; n Ruiz-de-Gauna
• 关键词：Anemia ; Ferropenia ; Hierro sacarosa ; Enfermedad renal cró ; nica avanzada ; Trasplante renal
• 刊名：Di谩lisis y Trasplante
• 出版年：2009
• 期刊代码：pca116_18862845
• 类别：med
• 出版时间：March 2009
• 卷：30
• 期：1
• 页码：8-10
• 文件大小：152 K

ss="h4">Aim

The aim of this study was to evaluate the use, safety and efficacy of intravenous iron administration in the nephrology outpatient consulting room in patients not under dialysis.

ss="h4">Patients and methods

Patients receiving intravenous sucrose iron (Venofer<sup>庐sup>) in the nephrology outpatient consulting room from January 2006 to March 2008 were included. Demographic data, iron dosages, treatment length and reasons for finishing the treatment were recorded.

ss="h4">Results

Sixty-three patients were included (2/3 males). A total of 119 dosage schedules were registered (81%of patients had 鈮?2 dosages). The most frequent amounts per dose were one ampoule (66%), two ampoules (33%) and a half ampoule (1%). The frequency of administration ranged between each week and every 4 months, while the most common frequency was monthly. Ferritin levels increased significantly (82.3 卤 83.5 vs. 217 卤 159.7 鈥?paired t-test; p < 0.001). At the end of the study, 28 patients continued to receive the treatment, while 14 had started on dialysis. No serious adverse effects were detected.

ss="h4">Conclusion

Intravenous iron administration in the nephrology outpatient consulting room is safe and effective.